ANX (2.29 +%15)- Anyone know the reason for the move?

my thanks to pcrutch is not about neop but just having his input on all the other ones ...

neop has been my baby since march/april of this year ... ive just been very patiently awaiting the NDA which is just around the corner (for the second time)...

a brief history on neop is that it had prior meetings with the fda to make sure nothing goes wrong with their nda submission. FDA told them to submit the nda with the clinical trial they had going which i believe was NEO3-05 ... they met several months later (in oct) for their final meeting pre-nda and the fda threw them a curve ball stating that it now wanted them to submit the data for NEO3-05 along with NEO3-09 together before submitting the NDA. This caused the PPS to drop since investors were expecting the NDA to be submitted in Oct.

However, because of this 03-05 study combination, it broadens the scope of their drug usage (given that the data for 09 comes out good) so it will have a larger market cap.

i still stand by my 4-7 pps range in 2011 1q
my previous post

VVUS - Ya'll should keep a watch on this one. Seems to be gaining momentum lately. I truly believe it will get a restricted labeling approval by the fda sometime in mid 2011.

NEOP - Still my #1 play of 2011 q1. Clinical trials will be out soon which will broaden their market cap. NDA will follow soon after ... and perhaps a AMEX listing and or RIGS update will set prices soaring

pcrutch, you are a great addition to this board. great job man!

... Uri Landesman keeps coming on CNBC and mentioning NEOP since the day of AVNR's approval (i know cause it was the first thing i was going to buy with my AVNR's earnings since its PPS was way too low ....sigh) and talking about how he believes a bidding war is coming between Cardinal and Covidien

video links
11/1 cnbc video

11/29 cnbc video


Also, insider buying has been going on recently ..

I have been waiting patiently on this one but i dont think i can sit around and wait for pps to drop again ... this one is going to take off real soon ... so bought some more shares today

I already purchased some @ 5.25 this morning thanks to pcrutch looks like a solid 15-25% upside play for me...

thanks pcrutch

That is excellent news!

With regards to NEOP, I believe this company will be up 300%+ within 6-8 months time. I believe the PPS will settle down to the low 1.50's (possibly even lower since new dilution has been set in).

However, with the NDA on Lymphoseek alone, this puppy will shoot up 100-150% sometime in the 1st quarter. Post approval, if the "superiority" claim that Bupp claims is true, this product alone will make the PPS shoot to 7-10 (hopefully by june). The recent NDA delay while unexpected, will help broaden the scope of lymphoseek market since they are including breast cancer screening.

This company is highly undervalued and it will be seen as one of those successful companies of 2011. (note: rigs 1 bill+ mkt potential is not included as part of my evaluation)

NEOP - Continues trucking along

Since Uri Landesman's appearance on CNBC (link below), the pps went from 1.50's to where its at now, 2.28

52 wk high is 2.32

video link ... plug is around the 3:11 mark

http://www.cnbc.com/id/15840232?video=1630400849&play=1

OT: (Non FDA) NYSE:LVS - I don't usually post OT, but man this company has been doing all the right things expect this to hit $75-80 pps this year

the only thing i can guess why its stuck at this price is because another institution may be selling at that price range for similar reasons that clarus did recently

all i have to say is that if you're still holding on... you have balls of steel .... just like me :)

yesterdays pps action i believe is a result of the sale of clarus shares were sold at the bid price (im assuming) in spurts ... this i believe, was a large reason for the impeding of the pps from moving higher

again, thats just my opinion

cadx

im calling a avnr type bear raid giving it a 25-35% haircut right before decision

keeping money aside to buy on a dip

this is what i see

http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.DrugDetails

RLD (which i imagine is Ruled)
should be yes/no .....

shouldnt it?

I was reading this article early this morning, however, I'm not buying into it ... seems like too much of a risky play to me...

article on seeking alpha

NEOP 1.57 - 1.59 Range

This will be trading anywhere between 4-7 in 3-5 months time. EOM.

it will be up after approval .. thats all i care about

also like to add this PR from nov 2009 with a section of it highlighted

Avanir Pharmaceuticals Announces Zenvia Safety And Efficacy Data From Star Trial Open Label Extension
Tuesday, 10 Nov 2009 08:30am EST
Avanir Pharmaceuticals announced the efficacy, safety and tolerability results from the 12 week open label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA). - Patients maintained on Zenvia 30/10 mg demonstrated statistically significant incremental improvement in their CNS-LS scores over the additional 12-week treatment period of the open-label study (p<0.0001). - Patients that titrated from Zenvia 20/10 mg to Zenvia 30/10 mg demonstrated statistically significant incremental improvement in their CNS-LS scores (p<0.0001). - Patients originally on placebo that initiated Zenvia 30/10 mg demonstrated statistically significant improvement in their CNS- LS scores (p<0.0001). - Zenvia 30/10 mg was generally safe and well tolerated with 92.9% of patients completing the 12-week treatment period of the open-label study. - Reported rates of adverse events (AEs) were low overall, mild to moderate in nature and consistent with the reported AEs in the double-blind phase. - The overall mortality rate observed in patients with amyotrophic lateral sclerosis, or ALS, (a terminal condition) was consistent with historic norms.

OT: Have ya'll seen the craziness of the solar stocks lately? (last few days)

good day for all of you wanting some money early next year.

neop going down for a minor delay on lymphoseek nda (fda delayed lymphoseek because they now want nda to include data from their on-going clinical trial NEO3-09 which was not part of their earlier arrangement)

this pps will not stay low for very long in my opinion

NEOP: Neoprobe Initiates Application for Listing on NYSE: AMEX

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative oncology surgical and diagnostic products, announced today it has initiated the application process for listing on the NYSE: AMEX stock exchange.

David C. Bupp, Neoprobe’s President and CEO, said, “A potential listing on NYSE: AMEX would serve as a positive milestone for our Company and would enhance shareholder value. A listing would provide greater market exposure, especially to institutional investors, and provide increased liquidity for our investors. We continue to work diligently with the officials at NYSE: AMEX to expedite the listing process. This may take a number of weeks to complete prior to receiving final approval for listing and will be dependent on our continued compliance with the qualitative and quantitative listing standards.”

As a result of recently becoming S-3 eligible, the Company announced it filed a shelf registration statement. In detailing the Company’s registration, Mr. Bupp said, “While our Lymphoseek development program is fully funded, the shelf registration provides our Company with flexibility to support our corporate objectives, including potentially funding our RIGScan CR development efforts. We have also included secondary shares from our primary investor, Platinum-Montaur Life Sciences LLC, as a means to diversify our institutional stockholder base to further support the stable appreciation of value for our shareholders.”

The Company also announced it will hold a conference call on Monday, August 9th at 5:00 PM ET to review 2nd quarter 2010 results. The conference call can be accessed as follows:


http://finance.yahoo.com/news/Neoprobe-Initiates-bw-2524155605.html?x=0&.v=1

This company (1.63 avg) is going to be one of my best investments thus far.

NDA is right around the corner... and so is $3.00+ PPS

NEOP: Neoprobe Announces Preliminary Second Quarter 2010 Revenue

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it expects to report revenue of approximately $2.6 million and $5.3 million for the second quarter and year-to-date in 2010, respectively. These revenues represent increases of 45 percent and 18 percent for each of the respective periods over the same periods in 2009. Increased sales volume of the Company’s base gamma detection systems, offset by slight price decreases, accounted for the increases in both periods.

Neoprobe cautions that these financial results are preliminary, are based on the best information currently available to the Company and are subject to completion of the second quarter financial statements and their review by Neoprobe’s independent registered public accounting firm. Neoprobe expects to announce complete second quarter and year-to-date 2010 operating results during the first week of August, 2010.

.... (more on website, cant copy paste)

NEOP: Neoprobe Completes CMC Data Review for Lymphoseek®

http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20100712005327&newsLang=en

One step closer to NDA

NEOP: Neoprobe Initiates Third Phase 3 Lymphoseek Study

http://finance.yahoo.com/news/Neoprobe-Initiates-Third-bw-3055171886.html?x=0&.v=1

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative oncology surgical and diagnostic products, today announced that a third multi-center Phase 3 clinical study of Lymphoseek® (NEO3-09) has received investigational review board approval and begun enrollment of subjects diagnosed with breast cancer or melanoma. The Phase 3 study has been registered on the national clinical trials website www.clinicaltrials.gov.

David Bupp, Neoprobe’s President and CEO, said, “This Phase 3 clinical study is designed to further validate Lymphoseek as a sentinel lymph node tracing agent. Data from this study is not required for the New Drug Application (NDA) for Lymphoseek, which we expect to begin filing with FDA later this summer. The initiation of the third Phase 3 study is another milestone in the development of Lymphoseek and we expect to achieve additional milestones in the coming months for this product.”

Fredrick O. Cope, Ph.D., Neoprobe’s Vice President, Pharmaceutical Research and Clinical Development, said, “NEO3-09 will study approximately 150 patients to provide a statistical sample size of 220 lymph nodes. One of the primary objectives of the Phase 3 study is to demonstrate the superiority of Lymphoseek in identifying lymph nodes draining from breast cancer or melanoma tumors compared to the vital blue dyes currently used in these procedures.”

NEO3-09 is designed to support post-marketing labeling for Lymphoseek after the approval of initial product labeling in the NDA. The first site has already been initiated and begun enrolling patients. In the coming weeks, an additional seven sites are expected to be initiated and commence patient enrollment. Initial results from NEO3-09 are expected to be available in the first quarter of 2011.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

NEOP.OB CNBC Clip
http://www.cnbc.com/id/15840232?video=1532083791&play=1

according to yahoo boards, NEOP was mentioned on CNBC hence the PPS today... in case any of you were wondering

anyone know whats going on with the volume/pps and why its jumping up so high with no news?

the fact that there was movement yesterday on no news at all after a dismal couple of weeks leads me to believe that there was some inside trading going on... which leads me to believe that this should be good news for us biel investors ... all just imo

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42248176

I'm calling it now ... today is the start of the uptrend

MIAMI, FL -- (MARKET WIRE) -- 10/27/09 -- Expert Group, Inc. (PINKSHEETS: EXPU) proudly announces it now offers Ginne Mae backed FHA loans.

Ginnie Mae securities are currently among the most secure investments in the global capital market. In 1934, during the depths of the Depression, Congress passed the National Housing Act to strengthen a deeply troubled housing market. An important element of this legislation was to make mortgage funds available to more Americans by protecting lenders from the risk of default. Ginnie Mae is the only agency to offer mortgage-backed securities backed by the full faith and credit of the United States government .

What Does This Mean For Expert Financing?

Expert Financing now offers FHA Loans to clients with a FICO score as low as 560 direct to Ginnie Mae . Overall, a score of 650 or above is a sign of a very good credit and is considered a good credit score. People with scores of 650 or higher will, all things considered, have a good chance of obtaining quality loans at the best interest rates.

With scores below 620, consumers may still obtain a loan. However, getting a loan in such cases is extremely tough, as creditors consider scores below this value to be an indication of greater credit risk.

Robert Rico stated: "The FHA Market is what is fueling the real estate recovery, but as we all know, in 2008 the credit scores of lots of hard working people were affected negatively by the national economic conditions. At present, low credit scores are a big obstacle for many of these people and keeps them from being approved for loans. As a certified FHA Lending institution that now offers Ginnie Mae Loans we have positioned ourselves as the best firm in the Florida marketplace to close more loans for more people. We are now partnered with over 50 lending agencies to find the absolute best deal for people, but more importantly we are able to find a loan that works, period. Our closing rate is high and will now be even higher."

For further information about Ginnie Mae , investors are invited to visit the following link: http://www.ginniemae.gov

Robert Rico concluded: "Being able to offer low FICO Ginnie Mae backed loans means more loan closings for Expert. We project that we will do up to 20% more loan closings per month as a result. It also further establishes our credibility and the fact that we are a player in the Florida lending marketplace. Not every lender is able to offer loans of this nature. We had to go through a rigorous application process, followed by an inspection and interview process. Additionally, we must regularly provide audited financials and I plan to make these documents available to our shareholders and other interested parties at http://www.expertgroupblog.com."

About Expert Group, Inc.

Expert Group, Inc. markets a variety of financial products and services through Expert Financing & Investments, Expert Group Title Services and Expert Credit Fix U.S.A. Expert is licensed by the Department of Financial Regulations and a member of FAMB, FHA and VA Lender.

About Expert Financing:

Expert financing offers up-to-date loan programs tailored to all borrowers' needs, specializing in Fannie Mae , Freddie Mac , FHA, conventional and non-conventional loans of all sizes. An Expert Loan Officer can help you find the best Loan for your needs.

About Expert Credit Fix U.S.A.

Expert Credit Fix U.S.A is ahead of the game, assisting borrowers with less than perfect credit to fulfill their dream of home ownership. Expert Credit Fix U.S.A. will help borrowers restore their credit to a level where lenders will grant them credit and at a low interest rate.


Expert Financing Locations: 17501 Biscayne Blvd #540 North Miami Beach, Fl 33160 1065 Kane Concourse Bal Harbour, FL 33180 19501 Biscayne Blvd Miami, FL 33180-2377


Certain statements in this release and the attached corporate profile that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (I) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors.

Contact: Expert Group, Inc. www.ExpertFinancing.net www.ExpertCreditFixUSA.com or call: 305-949-LOAN (5626)

Tuesday, October 27 2009 8:00 AM, EST ZYTO Corp Announces a 325% Increase in Profits for Q3 2009 Business Wire    "US Press Releases "

OREM, Utah --(BUSINESS WIRE)-- ZYTO Corp (Pink Sheets:ZYTC) (www.ZYTO.com) announces an EBITDA profit of $234,021 for the third quarter of 2009, up 325% as compared to the same period last year. Total revenue for the third quarter of 2009 was $1,106,260 , up from $532,548 in revenue for the third quarter of 2008.

Revenue for the nine months ended September 30, 2009 is $2,347,605 , up 64 percent from the same period last year.

According to Kami Howard , CFO, "These results show the effectiveness of our focus on marketing, sales, and after-sales support. By having a back-end revenue model that increases profits for ZYTO each month, we have the ability to provide ongoing service, support, and training to facilitate our customer's success."

"Our business model keeps us engaged long term with our customers. As to any business, customer loyalty and retention is invaluable. We believe the current business growth, plus the anticipated growth of our products places ZYTO Corp on a strong annual growth path for the next several years," stated Dr. Vaughn R Cook, CEO.

ZYTO has sales efforts underway in the United States , Canada , Latin America , China , South Africa , Australia , and Europe . Sales and subscription fees are the current primary sources of liquidity. ZYTO's sales force is comprised of an in house sales staff and independent sales representatives.

About ZYTO Corp

ZYTO Corp was founded by Dr. Vaughn R Cook, OMD. The company provides decision support technology. For more information about ZYTO, visit www.ZYTO.com or contact their Headquarters at 801-224-7199.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.





Source: ZYTO Corp

Joseph F. Finn, Jr., Assignee for the Benefit of Creditors of EPIX Pharmaceuticals, Inc., Releases Statement Regarding Liquidation Process PR Newswire    "US Press Releases "


WELLESLEY HILLS, Mass. , Oct. 22 /PRNewswire/ -- The previously announced auction of assets of EPIX Pharmaceuticals, Inc. was conducted on October 21, 2009 . As of today, claims filed against the estate far exceed the assets available for distribution to creditors. The Assignee will continue to liquidate assets and review the claims filed against the estate, but at this juncture, it does not appear that creditors will be paid in full or that there will be any assets available for distribution to shareholders of EPIX Pharmaceuticals .



On July 20, 2009 , EPIX Pharmaceuticals, Inc. (the "Company") entered into an Assignment for the Benefit of Creditors (the "Assignment") in accordance with Massachusetts law. The purpose of the Assignment is to conclude the Company's operations and provide for an orderly liquidation of its assets. The Assignment is a common law business liquidation mechanism under Massachusetts law that is an alternative to a formal bankruptcy proceeding. Under the terms of the Assignment, the Company transferred all of its assets to an assignee for orderly liquidation and distribution of the proceeds to the Company's creditors. The designated assignee for the Company is Joseph F. Finn, Jr. at Finn, Warnke & Gayton, 167 Worcester Street , Suite 201, Wellesley Hills, MA 02481.



About Joseph F. Finn, Jr. , C.P.A.



Joseph F. Finn, Jr. , C.P.A. is the founding partner of the firm Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts . He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidation agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc. , ActivBiotics, Inc. and Prospect Therapeutics, Inc.



CONTACT: Joseph F. Finn , +1-781-237-8840



SOURCE Joseph F. Finn, Jr. , C.P.A.

NEWS...

Expert Group, Inc. Prepares to Receive Prestigious Award at Ribbon Cutting Ceremony Market Wire    "US Press Releases "
MIAMI, FL -- (MARKET WIRE) -- 10/21/09 -- Expert Group, Inc. (PINKSHEETS: EXPU) is proud to announce that the Grand Opening Ribbon Cutting Ceremony will be held on Monday, November 16, 2009 at the new Expert Financing Mortgage Lending Center located in Bal Harbour, Florida .

During the ceremony, Expert Financing will receive the highly respected "Proclamation Award" from the city of North Miami Beach . North Miami Beach will present the award as well as the "Key to the City" to Robert Rico and Expert Financing. Local officials, dignitaries, and other personages are planning to attend the event. Expert Group predicts that several hundred guests will attend throughout the day and would like to extend a warm welcome to every shareholder past, present, and future to join us for the celebration.

CEO Robert Rico stated: "This award is important to us on several levels. First, it puts Expert on greater display within the Florida marketplace. This is the kind of marketing that money simply cannot buy and it is very good for new business! Secondly, the award establishes our company's credibility and ethical business growth. The award places us in a 'cream of the crop' category as we join only a handful of other extremely credible businesses that have won the award."

The ceremony will be recorded and available on the company blog page www.expertgroupblog.com as well as on our corporate website that has just been updated with our new locations and programs.

On other company news the company will be updating its Pink Sheets information within the next two weeks in order to upgrade our status from "limited information" to the transparent "current information" category. Expert Group also commits to increasing its efforts to expand its investor base during these exciting times of company growth.

CEO Robert Rico concluded: "My primary responsibility as CEO is to grow the business, increase company income, and enhance shareholder value. I'm doing that. We have 16 closings scheduled before the month ends. I am hard at work in securing and training new originators for our Bal Harbour offices. I am diligently working to close multi-million dollar jumbo and commercial deals. But as an investor myself I also know what investors want to see and why they want to see it. So I am crunching numbers today and commit to giving our investors what they want: I plan to provide Q3 numbers before the end of the month. I will also offer some guidance by giving Q4 projections."

About Expert Group, Inc.

Expert Group, Inc. markets a variety of financial products and services through Expert Financing & Investments, Expert Group Title Services and Expert Credit Fix U.S.A. Expert is licensed by the Department of Financial Regulations and a member of FAMB, FHA and VA Lender.

About Expert Financing:

Expert financing offers up-to-date loan programs tailored to all borrowers' needs, specializing in Fannie Mae , Freddie Mac , FHA, conventional and non-conventional loans of all sizes. An Expert Loan Officer can help you find the best Loan for your needs.

About Expert Credit Fix U.S.A.

Expert Credit Fix U.S.A. is ahead of the game, assisting borrowers with less than perfect credit to fulfill their dream of home ownership. Expert Credit Fix U.S.A. will help borrowers restore their credit to a level where lenders will grant them credit and at a low interest rate.

Expert Financing Locations:


17501 Biscayne Blvd #540 North Miami Beach, Fl 33160 1065 Kane Concourse Bal Harbour, FL 33180 19501 Biscayne Blvd Miami, FL 33180-2377

the data is not compromised... the hard drives are encrypted as well as the data that contain the information... laptops are stolen more often then you would think ... this report is just something to write about and nothing else

http://www.marketwire.com/press-release/Expert-Group-1060141.html

Expert Group, Inc. Opens Third Location, Forecasts an Additional $3,000,000 in Annual Revenues

MIAMI, FL--(Marketwire - October 15, 2009) - Expert Group, Inc. (PINKSHEETS: EXPU) is proud to announce the official grand opening of its new Expert Financing Mortgage Lending Center located in Bal Harbour, Florida. The new center is a highly visible storefront location centrally located at 1065 Kane Concourse. The new offices are next door to Coldwell Banker Realty and Turnberry International Realty.
Expert Group has already secured 15 new originators for this new location. This new location will house a total of approximately 50 originators.
Robert Rico, CEO of Expert Group, stated: "It's very simple, really. More originators mean more originations. More originations mean more closings. More closings mean more income. We are beaming with pride and excitement as we announce the opening of this new office location. This marks a major milestone in the company's 5-year history. We are taking all the right steps necessary to fulfill our business plan of opening multiple locations and branding Expert Financing as the go-to firm for all your Real Estate Lending Needs."
Originators are compensated based on performance. Originators do not get paid if they do not close loans. Expert Group realizes between $4,000-6,000 in revenue per closed loan. With 50 additional originators operating at the new location Expert Group projects 50 new loan closings per month. Using the mean figure of $5,000 per loan closing, this means an additional $3,000,000 in annual revenue from this new location, alone.
Robert Rico stated: "It's important to me that investors realize these projections are backed by several years' worth of hard data from our other location. Frankly, I believe these estimates to be conservative as they do not take into consideration jumbo loans or commercial loans, of which we are working on closing several."
Expert Group plans to update the blog and twitter pages with pictures and videos of the new location. Please stay tuned at http://www.expertgroupblog.com and http://www.twitter.com/expertgroup for updates.
Robert Rico concluded: "As I wrap up this latest update, let me again thank our loyal shareholders for helping us to build a profitable company. Our company is quickly expanding yet growing responsibly. We are successfully branding the 'Expert Financing' name all over the Florida marketplace. We offer people the absolute best deal on home loans. Our closing ratio is higher than other lenders. We're here to stay. I extend a standing invitation to investors to call, write, or visit. I read all investor correspondence and welcome all suggestions. Additionally, I am always happy to help find a home loan solution for you no matter the state in which you live."
About Expert Group, Inc.
Expert Group, Inc. markets a variety of financial products and services through Expert Financing & Investments, Expert Group Title Services and Expert Credit Fix U.S.A. Expert is licensed by the Department of Financial Regulations and a member of FAMB, FHA and VA Lender.
About Expert Financing:
Expert financing offers up-to-date loan programs tailored to all borrowers' needs, specializing in Fannie Mae, Freddie Mac, FHA, conventional and non-conventional loans of all sizes. An Expert Loan Officer can help you find the best Loan for your needs.
About Expert Credit Fix U.S.A.
Expert Credit Fix U.S.A is ahead of the game, assisting borrowers with less than perfect credit to fulfill their dream of home ownership. Expert Credit Fix U.S.A. will help borrowers restore their credit to a level where lenders will grant them credit and at a low interest rate.
Expert Financing Locations:
17501 Biscayne Blvd #540
North Miami Beach, Fl 33160

1065 Kane Concourse
Bal Harbour, FL 33180

19501 Biscayne Blvd
Miami, FL 33180-2377
Certain statements in this release and the attached corporate profile that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (I) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors.

I agree

I sincerely doubt this company is not a "game". This company is as real as they come. I just disagree with the way they handle PR is all. So like I said before, I'll just let the numbers do the talking.

From my perspective, the problem seems to be that Rico thinks that "tweeting" or "blogging", he is going to keep his investors satisfied. This company needs a true PR representative to keep the investing world up to date with their advancements.

The company is solid at the moment and it seems to have great potential (which is why I'm still here), however, this "here's the floor plans" or "news coming out soon" which leads to another "blog" update does not cut it in my opinion. I'm just going to stick around and wait for the numbers to come out.